BioSpace News Archive

Company to Host Virtual Event on December 7, 2021 Beginning at 9:00 a.m. ET.

AbbVie (NYSE:ABBV) today announced it has submitted an application to the European Medicines Agency (EMA) seeking approval for risankizumab (SKYRIZI®.

ImmunoPrecise Update on its SARS-CoV-2 PolyTope™ Multi-Antibody Cocktail Development Program.

Lineage Reports Fourth Case of Retinal Tissue Restoration With OpRegen ® .

Delcath Systems, Inc., an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, announced its agenda and distinguished speaker list for a comprehensive Investor Update Meeting taking place Thursday, December 2nd, from 10:00am ET – 1:30pm EST.

Codiak BioSciences, Inc. today announced that the U.S. Food and Drug Administration (FDA) has cleared the company’s Investigational New Drug Application (IND) for exoASO-STAT6.

Numinus Wellness Inc. today announced that it will participate in the H.C. Wainwright 2 nd Annual Psychedelics Conference to be hosted virtually on Monday, December 6, 2021.

Iterative Scopes announced that it has CE marked its SKOUT medical device under the MDD after successfully completing the assessment of the conformity of the device with the applicable MDD requirements in April 2021.1 This milestone marked the product’s first regulatory certification and will enable its distribution and marketing in Europe, a key step in Iterative Scopes’ global expansion plans.

AgeX Therapeutics, Inc. announced today that ImStem Biotechnology, Inc. (“ImStem”), a biopharmaceutical company developing human embryonic stem cell (ESC)-derived mesenchymal stem cells, has dosed the first U.S. multiple sclerosis (MS) patient with ImStem’s lead investigational drug candidate IMS001 at the Shepherd Center in Atlanta, GA.

Alzamend Neuro, Inc. (Nasdaq: ALZN) (“Alzamend”), today announced that it has received confirmation that topline data for its Phase 1 clinical trial for AL001 for dementia related to Alzheimer’s will be delivered mid- to late-December 2021.